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ABSTRACT
Background: Hepatitis C genotype 4 (HCV-4) is considered to be rare outside northern Africa 
and southern Europe.
Objectives: To describe the epidemiological characteristics of patients infected with HCV-4 in 
Poland.
Patients and Methods: The study group included 290 patients with HCV-related chronic liver 
disease and intravenous drug users with HCV infection recruited in years 2002-2006 in Pod-
laskie region, north-eastern Poland. In all cases, HCV infection was confirmed by HCV-RNA 
detection by qualitative nested RT-PCR. HCV genotype was determined by 5'UTR sequencing 
and comparison with known genotype-specific sequences.
Results: HCV 4 was found in 45 (15.5%) of 290 HCV-infected and HCV RNA-positive individuals. 
60% of HCV 4 infections occurred in intravenous drug users; 51% of HCV 4-infected patients 
were also HIV-positive. Among 119 patients whose source of infection was other than drug 
use, there were 16 (10.5%) HCV 4 cases. Seven (46%) of 13 HCV 4-positive and HIV-negative pa-
tients who received combined antiviral treatment had sustained viral response.
Conclusions: HCV 4 exists in eastern Poland, and the infection is frequently related to intra-
venous drug use and accompanied by HIV infection. HCV 4 also causes a proportion of non-
drug-related HCV infections.
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Background
Hepatitis C is a major cause of end-stage liver disease in 
many parts of the world. Six genotypes 1–6 of hepatitis C virus 
(HCV) have so far been described (1). Overall, HCV genotype 4 
(HCV 4) represents approximately 20% of the global HCV in-
fection (2). It is common in the Middle East and sub-Saharan 
Africa. In Egypt, it is responsible for almost 90% of HCV infec-
tions (3), and has recently spread to several European coun-
tries (4-7). The majority of HCV 4 infections in Egypt resulted 
from parenteral antischistosomal therapy while most of the 
Europeans acquired the infection through illicit drug use 
(8). Some studies have indicated a potential link between in-
fection with HCV 4 and higher risk of development of hepa-
tocellular carcinoma (9). Little epidemiological information 
concerning HCV 4 infection in eastern Europe is available. 
Our earlier report demonstrated decrease of relative pro-
portion of genotype 1, and increase in genotype 3 over time 
and confirmed presence of genotype 4 in north-eastern Po-
land (10). We also reported on a high prevalence of genotype 
4 among HCV-infected intravenous drug users (11). HCV 4 is 
considered  difficult-to-treat  genotype  like  HCV-1.  Patients 
with HCV 4 genotype are underrepresented in large clini-
cal trials because of the rare prevalence of this genotype in 
Europe and the US. In addition, antiviral treatment may be 
negatively affected by frequent co-infection with HIV (8).
  Implication for health policy/practice/research/medical education: 
Understanding the geographical distribution of different HCV genotypes all over the world can guide virologists, geneticians and infectious 
specialists to better analyze the epidemiology of HCV in patients.
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Objectives
The objective of this study was to further elaborate on epi-
demiological features of HCV genotype 4 infections in Po-
land, to determine factors associated with HCV 4 infection 
not related to drug use and to describe antiviral treatment 
response in patients infected with HCV 4.
Patients and Methods
The study took place in Podlaskie voiewodship (adminis-
trative area in north-eastern Poland, with 1,200,000 inhabit-
ants). Subjects included anti-HCV-positive individuals seen 
at the Department of Infectious Diseases and Hepatology of 
the Medical University of Bialystok and HCV-infected clients 
of the drug treatment center near Bialystok (Monar, Zacz-
erlany) in years 2002–2006. All subjects were interviewed 
using a structured questionnaire. The risky exposures con-
sidered  in  our  study  were  intravenous  drug  use,  transfu-
sions of blood or blood products before 1993 (routine blood 
screening was introduced in Poland in 1992), incarceration 
and tattoos. The diagnosis of hepatitis C was based on the 
presence  of  anti-HCV  antibodies  (ELISA,  third  generation 
test, IMx MEIA, Abbott, Chicago, USA) and was confirmed by 
HCV-RNA testing (qualitative nested RT-PCR) as previously 
described (8, 9). HCV genotypes were determined by direct 
nucleic acid sequence analysis of nested-PCR products from 
5'UTR, as previously described in detail (8, 9). The INNO-LIPA 
HCV II hybridization test (Innogenetics, Belgium) was also 
used in our study to confirm the results of HCV genotyping 
by 5'UTR sequencing for 19 patients and concordant results 
were obtained. The statistical calculations were performed 
with the use of statistical package Statistica 7.1 (Statsoft, Tul-
sa, OK, USA). x2 test (with Yate’s correction when appropriate) 
was used for analysis of differences in risk factors between 
groups with genotype 4 and other genotypes.
Informed consent was obtained from each participant and 
the study protocol was approved by the Ethical Committee 
at the Medical University of Bialystok. A p value <0.05 was 
considered statistically significant.
Results
Among 290 patients with HCV infection who had HCV gen-
otype  determined,  there  were  45  (15.5%)  patients  infected 
with genotype 4, 146 (50.3%) with genotype 1 and 99 (34.1%) 
with HCV 3. The majority of patients with genotype 4 had 
similar  characteristics  to  those  infected  with  other  geno-
types and were males (69%) aged between 31 and 50 years of 
age (66.7%) poorly educated (basic education or lower sec-
ondary 55.6%) (Table 1). The mean age of patients with HCV 4 
and those infected with other than HCV 4 genotype was not 
significantly different (34 and 36.9 years, respectively). Over-
all 60% of HCV 4 infections occurred in patients with prior 
intravenous drug use while 37.6% of infections with other 
genotypes were drug-related. In 119 patients whose source 
of infection was other than drug use, there were 16 (10.5%) 
HCV 4 cases. The majority (51%) of HCV 4 individuals were 
also HIV-positive (28.9% in case of other genotypes) (Table 
1). Among 94 patients with HCV/HIV co-infection, HCV 4 was 
present in 23 (24.5%) individuals. Thirteen of HCV 4-positive 
patients who were HIV-negative and never received treat-
ment for HCV (9 men, 4 women, mean ± SD age of 41.6±11.9 
years) received combined antiviral treatment (Peg-IFN α-2a 
120–180 µg/week, Peg-IFN α-2b 100–150 µg/week or natural 
IFN α 9 MU/week with ribavirin (800–1200 mg/day based on 
body weight). HCV RNA was assessed at baseline, and after 3, 
12 and 18 months of start of the treatment. In three (23%) pa-
tients the treatment was stopped after three months due to 
lack of response (defined as at least 2 log10 reduction in HCV 
RNA at week 12). End-of-treatment viral response (defined 
as negative for HCV RNA at the end of 48 week therapy) was 
achieved in nine (69%) patients and sustained viral response 
(defined as negative for HCV RNA six months after end of 
therapy) in six (46%) patients.
Discussion
We found that 15.5% of HCV individuals in north-eastern Po-
land harbored genotype 4. Overall 60% of HCV 4 infections 
in the present study were associated with intravenous drug 
use and further 13% were related to transfusions. The associa-
tion with drug use which was shown in our previous report 
(11) is in accordance with the studies from Western Europe. 
For example, 57% of 134 patients of French origin infected 
with genotype 4 were drug-related and further 18.8% result-
ed from transfusion (7). In a US study, 12 (60%) of 20 patients 
with HCV 4 had a history of illicit drug use (12); the drug use 
however, is not the major risk factor for infection with geno-
type 4 in Africa. More than 90% HCV 4-infected Egyptian im-
migrants in France had no history of drug use; their major 
risk factor was a history of parenteral treatment for Schisto-
soma mansonii in childhood or adolescence (7). In a study of 
112 patients with HCV 4 from Kuwait, researchers reported 
a high proportion of individuals with Egyptian nationality, 
but none were intravenous drug users (13). Our group of pa-
tients with HCV 4 did not include any immigrants. HIV infec-
tion (also related to drug use) was another risk factor asso-
ciated with infection with genotype 4. HCV 4 exists in 24.5% 
of subjects with HCV/HIV co-infection. A high prevalence of 
genotype 4 was previously noted in HIV and HCV co-infected 
injection drug users in northern Spain (32/105, 30.5%) (4). 
However, other studies of HIV/HCV co-infection reported a 
lower prevalence of HCV 4—8.3% in France (7), 13% in Spain 
(6) and 14 % in the US (14). HCV 4 also caused 10.5% of HCV 
infections in non-drug users. The prevalence of genotype 
4 in Europe reported in other studies ranged between 2.7% 
(34/1239) in upper Austria—all HCV 4 patients in this study 
came from Egypt (15), 7.4 % in southern France (16) and 13.2% 
in Greece (17). In the 1999 Polish study, there were only 38 cas-
es of genotype 4 (2.7%) among 1385 individuals. Most of these 
HCV infections were probably not related to drug use (18). 
In another report from Poland, 7% of patients undergoing 
treatment for chronic hepatitis C were infected with geno-
type 4 (19). Our data indicates that the prevalence of HCV 
genotype 4 is increasing in Poland. Outside Europe and the 
Middle East, presence of HCV 4 caused 7.2% of HCV infections 
in 1998–2002 in some areas in India (20). In contrast, geno-
type 4 represented only 4 of 899 (0.4%) of HCV infections in 
Japan (21). The distribution of HCV genotypes is of particu-
lar importance, since genotypes vary in their response to 
treatment. In our study the sustained viral response rate to 
combined treatment with interferon and ribavirin was 46% 
(6/13). This is very similar to the sustained viral response of 
43.4% reported by Roulot, et al, in France (data of 242 naïve 
patients treated for 48 weeks with pegylated interferon and 
ribavirin) (7). Recent reviews suggest that HCV 4 may display Hepat Mon. 2011;11(3):191-194
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an intermediate sensitivity to treatment, because it is more 
sensitive to treatment than genotype 1, but exhibits a lower 
sensitivity to treatment than the genotype 2 or 3 (22, 23). Our 
study has some limitations. First, a bias in patient selection 
might  not  represent  the  whole  HCV  epidemic  in  Poland. 
High number of drug users and HIV-infected individuals in 
the study may skew the prevalence of HCV 4. The treatment 
described included different regiments and only a small sub-
group of HCV 4 patients was treated with antiviral drugs.
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